ClinicalTrials.gg
RecruitingNCT07715955ProBiSatUpdated Aug 12, 2026

Effect of Probiotics on Appetite Regulation in Adults With Overweight/Obesity

An interventional study of Probiotic supplementation and Placebo in Healthy, Overweight (BMI > 25) and Overweight , Obesity, sponsored by Maastricht University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-12.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Obesity by Maastricht University Medical Center — 4 open to participants now, 4 under way, none of them phase 3. Obesity · Maastricht University Medical Center.

Planned enrollment
5th of 67
98 · median 40
Started
2026
with 1 other
No phase
65 of 75
4 open now
Registered
74th of 75
by date

Among the 75 studies in Obesity by Maastricht University Medical Center, this one is the 5th largest by planned enrollment of the 67 interventional ones that give a count, is one of 2 that started in 2026, is one of 65 with no phase, and was the 74th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 75 studies in Obesity by Maastricht University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Obesity by Maastricht University Medical Center, or all of them as a file.
02

Study summary

The goal of this 16-week randomised, placebo-controlled parallel study is to investigate the effect of a newly formed probiotic supplement on satiety and gut microbiota composition in healthy men and women with overweight or obesity form 20-70 years old. The main question it aims to answer is:

Does the probiotic supplement increase feelings of satiety and alter gut microbiota composition?

Participants will:

  • Receive a daily dose of 6 g probiotic supplement (packed in sachets of 3 g) or placebo for 16 weeks.
  • Visit the research unit 3 times at baseline, week 8 and week 16 of the intervention for blood draws and delivering fecal samples.
  • Keep a study diary to report deviations from their daily habits and fill in food questionnaires.
Read the detailed description

Rationale: Satiety hormones, including glucagon-like peptide-1 (GLP-1), are key regulators of food intake. Deficiencies in the release of satiety hormones as well as alterations in the composition and the function of the gut microbiota are hallmarks of overweight and obesity. Probiotics can improve the overall structure of the gut microbiota, and show strain-specific differences with regard to their ability to stimulate satiety hormones. Those animal-based findings, if confirmed in human studies, may pose a gateway for decreased food intake, weight management, and ultimately weight loss. The investigators hypothesise that a newly developed combination of probiotic strains, specifically selected for their potential to (in vitro) influence pathways related to weight management, will decrease food intake through increased release of satiety hormones (i.e. GLP-1) and beneficial alteration of the gut microbiota in humans.

Objective: The primary objective of the study is to investigate the effects of a combination of specifically selected probiotic strains in a new probiotic formulation on ad libitum food intake, in individuals with overweight and/or obesity. The investigators will address this objective firstly with an acute study followed by a proof-of-concept 4-months intervention study comparing a total of 98 individuals in a 16-week randomised, placebo-controlled parallel study (49 participants probiotic/ 49 participants placebo).

Study design: This intervention study will have a randomised, controlled parallel design. The total study duration will be 16 weeks.

Study population: A total of 98 men and women between the ages of 20-70 years old, with overweight/obesity (BMI: 26-40 kg/m2) will be recruited, accounting for a drop-out rate of 20%.

Intervention: Study participants will receive a daily dose of 6 g probiotic supplement (packed in sachets of 3 g) or placebo for 16 weeks.

Main study parameters/endpoints: At baseline and after 16 weeks, participants will visit the research facilities for assessments. The primary endpoint is the difference in satiety measured by ad libitum food intake comparing the probiotic and control intervention. Secondary outcome parameters are related to changes in satiety hormones (including GLP-1), fecal microbiota analysis, insulin sensitivity (HOMA-IR), inflammatory markers and lipid metabolism.

Exploratory outcomes concern perceived satiety, body composition and mental health. This study will provide insight into the potential beneficial effect of a newly composed probiotic supplement on satiety in overweight/obese adults.

03

Conditions studied

  • Healthy
  • Overweight (BMI > 25)
  • Overweight , Obesity
  • Male
  • Female
  • Adults
  • Satiety and Food Intake
  • Gut Microbiota Modulation

Browse trials for

Keywords

  • Probiotics
  • Overweight
  • Obesity
  • Adults
  • Healthy
  • Satiety
  • Food intake
  • Gut microbiota
  • Gut microbiota composition
  • Gut microbiota modulation
04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 98 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, aged between 20-70 years
  • ³ 25 kg/m2
  • Stable body weight (weight gain or loss \< 3 kg in the past three months)
  • Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study
  • No difficult venipuncture as evidenced during the screening visit

Exclusion criteria

Exclusion Criteria:

  • Diabetic patients (type 1 and type 2)
  • Abuse of drugs
  • More than 2 units alcoholic consumptions per day for women and 3 for men
  • Use of products or dietary supplements known to interfere with the main outcomes 3 months prior to the start of the study as judged by the principal investigators
  • Gastrointestinal disease (including IBD and IBS)
  • Use of an product within another biomedical intervention trial within the previous 1-month
  • Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, , disease and rheumatoid arthritis
  • Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident
  • use of lipid- and glucose lowering medication, use
  • Psychiatric diagnoses including clinical depression
  • Intolerances or dietary habits that might interfere with the study (i.e. lactose intolerance or veganism)
  • pregnancy
  • smoking, vaping
  • use of antibiotics up to 3 months prior to the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    Probiotic supplement

    6g of probiotic supplement daily

    Dietary Supplement: Probiotic supplementation

  • Placebo comparator
    Placebo

    6g of placebo daily

    Other: Placebo

Interventions

  • Dietary supplementProbiotic supplementation

    16-week consumption of 6 g/day of probiotic supplement

  • OtherPlacebo

    16-week consumption of 6 g/day of placebo

07

What researchers measure

Primary outcomes

  1. Ad libitum food intake

    The primary objective of the study is to investigate the effects of a combination of specifically selected probiotic strains in a new probiotic formulation on ad libitum food intake, in individuals with overweight and/or obesity. The primary endpoint is the difference in satiety measured by ad libitum food intake comparing the probiotic and control intervention.

    Time frame: From enrolment to the end of the 16-week intervention

Secondary outcomes

  1. Satiety hormones

    Satiety hormones, GLP-1, PYY, and ghrelin, will be measured in the blood by taking fasted and postprandial blood samples at multiple timepoints.

    Time frame: From enrolment to the end of the 16-week intervention

  2. Subjective Appetite Sensation

    Visual Analogue Scales (VAS) will be used to register different aspects of appetite, thirst, and well-being during the test days. The questions concern hunger, satiety, fullness, thirst, prospective food consumption, and desire to eat. Using a validated, 100-mm line, participants place a mark on the line between anchors like "not at all" (0 mm) and "extremely" (100 mm). Appetite sensation will be assessed at 30-minute intervals starting at time -30 until the ad libitum lunch for a total of 240 minutes.

    Time frame: From enrolment to the end of the 16-week intervention

  3. Fecal microbial composition

    Stool samples will be collected at home and immediately stored in the freezer at -20°C. Participants will bring the stool sample to the laboratory, while preserving the cold chain, where samples will be kept in a -80°C freezer until further analysis. We will profile the gut microbiota composition at baseline and after treatment using 16S rRNA gene amplicon sequencing techniques. Sequencing data will be processed using our validated in-house Bio-IT pipeline and microbial richness, diversity, community structure and taxonomic composition will be linked to the probiotic intervention as well as treatment outcomes.

    Time frame: From enrolment to the end of the 16-week intervention

  4. Diet

    Participants will be instructed to continue their usual dietary pattern throughout the intervention period to study the isolated effect of probiotic supplementation. Before, at week 8 and in the last week of the intervention period, participants' dietary pattern will be assessed by means of a FFQ.

    Time frame: From enrolment to the end of the 16-week intervention

  5. Physical Activity

    Participants will be instructed to continue their usual physical activity pattern throughout the intervention period to study the isolated effect of probiotic supplementation. Before, at week 8 and in the last week of the intervention period, participants' physical acitivity pattern will be assessed by means of the SQUASH questionnaire.

    Time frame: From enrolment to the end of the 16-week intervention

  6. Insulin resistance

    Fasted blood samples for glucose and insulin will be taken to determine the homeostatic model assessment of insulin resistance (HOMA-IR) and beta-cell function.

    Time frame: From enrolment to the end of the 16-week intervention

  7. Blood pressure

    Office BP (SBP and DBP) will be determined in four-fold (the first measurement will be discarded, and the last three measurements will be averaged) using a semi continuous blood pressure monitoring device (Omron M7, CEMEX Medische Techniek, Nieuwegein, The Netherlands).

    Time frame: From enrolment to the end of the 16-week intervention

  8. Heart rate

    Heart rate (HR) will be determined in four-fold (the first measurement will be discarded, and the last three measurements will be averaged) using a semi continuous blood pressure monitoring device (Omron M7, CEMEX Medische Techniek, Nieuwegein, The Netherlands).

    Time frame: From enrolment to the end of the 16-week intervention

  9. Lipids

    Fasting and postprandial serum triacylglycerol (TAG) and total cholesterol (TC) and HDL-C concentrations will be measured.

    Time frame: From enrolment to the end of the 16-week intervention

  10. Inflammatory markers

    Plasma markers related to systemic inflammation will be measured in the blood to assess low-grade systemic inflammatory responses.

    Time frame: From enrolment to the end of the 16-week intervention

  11. Body Composition

    Measurement of body composition is done by BodPod in a fasted state.

    Time frame: From enrolment to the end of the 16-week intervention

  12. Anthropometric measurements - Body weight

    Body weight will be measured in kilograms before the measurements without shoes and heavy clothing.

    Time frame: From enrolment to the end of the 16-week intervention

  13. Anthropometric measurements - length

    Length will be measured in centimeters before the measurements without shoes and heavy clothing.

    Time frame: From enrolment to the end of the 16-week intervention

  14. Anthropometric measurements - waist and hip circumferences

    Waist and hip circumferences will be measured in centimeters before the measurements using a SECA tape measure

    Time frame: From enrolment to the end of the 16-week intervention

  15. Mental health

    Mental health will be assessed using the validated Beck Depression (BDI) and State-Trait Anxiety Inventories (STAI).

    Time frame: From enrolment to the end of the 16-week intervention

  16. Mood

    Mood will be tested using the widely-applied Profile of Mood States (POMS).

    Time frame: From enrolment to the end of the 16-week intervention

  17. Stress

    Stress will be assessed using the Perceived Stress Scale (PSS).

    Time frame: From enrolment to the end of the 16-week intervention

  18. Sleep characteristics

    Sleep characteristics will be assessed at the end of the interventions using the Pittsburgh Sleep Quality Index (PSQI).

    Time frame: From enrolment to the end of the 16-week intervention

  19. Cognitive restrained

    Cognitive restrained, disinhibition and hunger will be assessed using the Dutch three factor eating questionnaire

    Time frame: From enrolment to the end of the 16-week intervention

  20. Disinhibition

    Cognitive restrained, disinhibition and hunger will be assessed using the Dutch three factor eating questionnaire

    Time frame: From enrolment tot he end of the 16-week intervention

  21. Hunger

    Cognitive restrained, disinhibition and hunger will be assessed using the Dutch three factor eating questionnaire

    Time frame: From enrolment tot he end of the 16-week intervention

  22. Quality of life assessment

    The quality of life will be assessed at the end of the interventions using a 32-item questionnaire. This measure will quantify quality of life on different dimensions: social, spiritual, emotional, cognitive, physical, activities of daily living, and integrated quality of life.

    Time frame: From enrolment to the end of the 16-week intervention

08

Study locations

1 of 1 sites recruiting
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2029, 41 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 41 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Jul 21, 2026
StartActual
Mar 18, 2026
Primary completionEst.
Aug 18, 2029
CompletionEst.
Aug 18, 2029
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07715955
Collaborators
Winclove Probiotics B.V.
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
Mar 18, 2026
Primary completion
Aug 18, 2029 (estimated)
Completion
Aug 18, 2029 (estimated)
Last update
Aug 12, 2026

Study contacts

Tanja Adam, PhD
Contact
t.adam@maastrichtuniversity.nl
+31433882123
Iris Boelen, MSc
Contact
iris.boelen@maastrichtuniversity.nl
+31433883644

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion